Skip to main content
Andre Goy, MD, Oncology, Hackensack, NJ, Hackensack Meridian Health Hackensack University Medical Center

AndreHGoyMD

Oncology • Hackensack, NJ

Hematologic Oncology

​Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service​, Chairman & Chief Physician Officer - John Theurer Cancer Center, Lydia Pfund Chair for Lymphoma, Academic Chairman Oncology- Hackensack Meridian School of Medicine, Professor of Medicine – Georgetown University

Request Appointment

Overview of Dr. Goy

As chairman and executive director of the John Theurer Cancer Center, and chief of the Lymphoma Division, I am optimistic about many of the recent breakthrough advances in cancer care, specifically in the area of immunotherapy. These treatments harness the immune system to fight cancer and include CAR-T cell therapy which has been very successful for patients who have failed all other lines of therapy. By combining data analytics, precision medicine and immunotherapy, our team can provide our patients with the best treatment options, in the most effective sequence, to successfully fight their cancer.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1995 - 1997
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterPost-Doctoral Fellowship, Laboratory of Molecular Hematology/Oncology, 1992 - 1995
  • Paris Hospital Cochin - Port Royal
    Paris Hospital Cochin - Port RoyalAttending Instructor, Hematology/Oncology/BMT, 1989 - 1991
  • Pasteur Institute, Paris VI University
    Pasteur Institute, Paris VI UniversityMS, Tumor Immunology, 1987 - 1989
  • Pasteur Institute, Paris VI University
    Pasteur Institute, Paris VI UniversityMaster's, Tumor Immunology, 1987 - 1989
  • Grenoble Medical School, University Joseph Fourier, Grenoble I, Domaine de la Merci
    Grenoble Medical School, University Joseph Fourier, Grenoble I, Domaine de la MerciMD, 1984 - 1988
  • Other
    OtherClass of 1988
  • Paris X University
    Paris X UniversityMS, Experimental Oncology, 1986 - 1987
  • Paris X University
    Paris X UniversityMaster's, Experimental Oncology, 1986 - 1987
  • University Alexis Carrel
    University Alexis CarrelCertificate, Immunology, 1985 - 1986
  • Grenoble University Medical Center
    Grenoble University Medical CenterResidency, Internal Medicine, HemOnc, Bone Marrow Transplantation, Emergency Room, Medical ICU, 1982 - 1983
  • Grenoble University Medical Center
    Grenoble University Medical CenterInternship, ICU, Internal Medicine, Neurology, Pediatrics, Gynecology and Obstretics, Emergency Room, Gastroenterology, Neurosurgery, 1978 - 1981
  • University Joseph Fourier, Grenoble I, Domaine de la Merci
    University Joseph Fourier, Grenoble I, Domaine de la MerciBS, 1975 - 1981
  • University Joseph Fourier
    University Joseph FourierBachelor's, 1975 - 1981

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2005 - Present
  • NY State Medical License
    NY State Medical License 1995 - 2026
  • NJ State Medical License
    NJ State Medical License 2004 - 2025
  • DC State Medical License
    DC State Medical License 2012 - 2024
  • Departmental Council of Paris, Order of PhysiciansBoard Certified in Hematology
  • Departmental Council of Paris, Order of PhysiciansBoard Certified in Internal Medicine
  • Departmental Council of Paris, Order of PhysiciansBoard Certified in Oncology

Awards, Honors, & Recognition

  • Inside Jersey Top Doctors for Cancer Castle Connolly, 2012-2016
  • America's Top Doctors Castle Connolly, 2009-2016
  • Top Doctors: New York Metro Area Castle Connolly, 2008-2016
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Ibrutinib for the Treatment of relapsed/refractory Mantle Cell Lymphoma: Extended 3.5-year Follow-up from a Pooled Analysis  
    Brad Kahl, Andre Goy, Haematologica
  • Venetoclax plus R- or G-CHOP in Non-Hodgkin Lymphoma: Results from the CAVALLI Phase 1b Trial  
    Andrew D Zelenetz, Andre Goy, Mehrdad Mobasher, Carla Casulo, Blood
  • Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration  
    Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Mil..., Am J Hematol., 1/1/2016
  • Join now to see all

Books/Book Chapters

  • Series: Emerging Cancer Therapeutics- Lymphomas 
    Goy, A.New York, NY2012
  • Bortezomib in the Treatment of Multiple Myeloma 
    Ghobrial, Irene M.; Richardson, Paul GEdition 1st,2011

Abstracts/Posters

  • Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
    Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
    Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
    Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • How I Think, How I Treat - BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond: Therapeutic Selection, Sequencing, and Next Steps 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Other

  • Complications of Monoclonal Antibodies in Hematological Malignancies 
    New Book Infectious Diseases in Immunocompromised Host
    1/1/2009
  • Diagnosis and Management of Other Lymphoproliferative Disorders. 
    Goy A H, Amin HM, Cabanillas F, Medeiros LJ, Non-Hodgkin’s Lymphomas
    1/1/2004

Press Mentions

  • HMH, St. Joseph’s Open Cancer Center of Totowa
    HMH, St. Joseph’s Open Cancer Center of TotowaMay 26th, 2023
  • St. Joseph’s Health and Hackensack Meridian Health Open Comprehensive Cancer Center at Totowa
    St. Joseph’s Health and Hackensack Meridian Health Open Comprehensive Cancer Center at TotowaMay 25th, 2023
  • How HMH Was Part of Highly Promising Potential Breakthrough in Melanoma Research
    How HMH Was Part of Highly Promising Potential Breakthrough in Melanoma ResearchApril 20th, 2023
  • Join now to see all

Professional Memberships

Other Languages

  • French, Spanish

Hospital Affiliations

External Links

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    AmeriHealth Direct POS
    Amerihealth HMO
    AmeriHealth PPO
    BCBS Blue Card PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Cofinity PPO
    Empire BCBS HMO
    Empire BCBS PPO
    First Health PPO
    GHI PPO
    Great West PPO
    HIP of New York - Select PPO
    Horizon BCBS Direct Access
    Horizon BCBS HMO
    Horizon BCBS POS
    Horizon BCBS PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    Oxford Health Freedom
    Oxford Health Liberty
    PriorityHealth HMO
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Andre Goy, Dr. Andre Goy, MD, Dr. A Goy, Dr. Andre H Goy